Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL7063395 | 0.87 | CSNK2A1 (0.37) | CYP2C9KDM4EALDH1A1HPGDNR4A2 | |
| SCHEMBL7063086 | 0.87 | NR4A2 (0.40) | CYP2C9KDM4EALDH1A1HPGDNR4A2 | |
| SCHEMBL2633339 | 0.81 | DYRK1A (0.43) | KDM4EALDH1A1HPGDNR4A2MAP2K1 | |
| SCHEMBL3016851 | 0.81 | PIM3 (0.46) | CYP2C9KDM4EALDH1A1HPGDNR4A2 | |
| SCHEMBL2628954 | 0.78 | KDM5A (0.38) | KDM4EALDH1A1NR4A2MAP2K1KDM5A | |
| SCHEMBL2628866 | 0.78 | KDM4C (0.44) | ALDH1A1NR4A2KDM5AKDM4CCYP19A1 | |
| Potassium SCHEMBL1762976 | 0.77 | KDM4C (0.43) | ALDH1A1NR4A2KDM5AKDM4CCYP19A1 | |
| Potassium SCHEMBL1763544 | 0.77 | KDM5A (0.37) | ALDH1A1NR4A2MAP2K1KDM5AKDM4C | |
| SCHEMBL1762972 | 0.77 | KDM4C (0.43) | ALDH1A1NR4A2KDM5AKDM4CCYP19A1 | |
| SCHEMBL1763541 | 0.77 | KDM5A (0.37) | ALDH1A1NR4A2MAP2K1KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257276-B1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6900323-B2 | Antiviral azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1257276-A4 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885KDM4E 462/4885ALDH1A1 1054/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | CYP2C9 3477/4885KDM4E 462/4885ALDH1A1 1054/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | CYP2C9 3466/4885KDM4E 493/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.